|
|
|
|
|
100+ participants
8 health agency speakers
21 sessions over 3 days
65% industry participation
28 hours total duration
7 hours networking time
› Request 2009 brochure
|
Conference:
Pre-conference workshop
8 December 9am - 5pm
Day 1
9 December 8am - 5.30pm
Day 2
10 December 8am - 5.30pm
Post-conference workshop
11 December 9am - 5pm
Venue: Royal Garden Hotel, London, United Kingdom
|
|
|
|
 Katia Finck,
Director, Market Access and Public Affairs, EMEA Shire Human Genetic Therapies Katia has 14 years professional experience in Pharma of which 11 years in Pricing & Reimbursement. She started her P&R experience in 1998, as an Economic Affairs Executive for a French company (Besins International). Then, from 2001 to 2005, Katia was part of the European Reimbursement Product Access Team for Allergan. During this time, she provided expertise, support and technical guidance to P&R activities at a European level. From 2005 to May 2007, Katia worked for GSK Biologicals, at the Brussels� headquarters, as a Senior P&R Manager. She developed global P&R strategies for new vaccines launches in line with commercial strategies.
In June 2007, Katia joined Shire Human Genetic Therapies in Basingstoke, UK, as Director of Market Access and Publics Affairs for EMEA. Her new position has two distinct areas of responsibility: Firstly, she is developing and implementing Pricing & Reimbursement strategies to facilitate the introduction of new Orphan Drugs into the EMEA region and sustain their value throughout their lifecycle. Secondly, she is providing and implementing Public Affairs strategies in the Orphan Disease community and is influencing policy and access for Shire HGT products in the region.
Katia has a Master's degree in Biochemistry, a Post-Graduate diploma in Pharmaco-Economy for Pharmaceutical Industry and a Post-Graduate diploma in Health Marketing. She was also trained at the "European School of Health Economics"" and the ""ESCP-EAP in negotiation skills."Appearing: Day Two - Thursday 10 December 2009 4.15pm HTA & Orphan Drugs: challenges from a company perspective
- Market access challenges in the field of Orphan Drugs
- Is conventional HTA appropriate for Orphan Drugs?
- How can we generate health economic outcomes?
Director, Market Access and Public Affairs, EMEA,
Shire Human Genetic Therapies |
|
|
|
Meindert Boysen
Associate Director Single Technology Appraisals
NICE
 Dr François Meyer Director, Health Technology Assessment Division
Haute Autorité de
Santé
 Dr Allan Korn Senior Vice President, Chief Medical Officer
BlueCross BlueShield Association
 Jerome Boehm Head EU level activities on HTA
European Commission
 Dr Matthias Perleth Head of Methods Department
Gemeinsamer Bundesausschuss
|
|
|
|
|
|
|
|
|
|
